APOA1 and breast carcinoma: Subsequently, they assessed the efficacy of ADV-ApoA1 in inhibiting TNBC growth and metastasis in several mouse models, including orthotopic breast cancer, spontaneous breast cancer, and human breast cancer xenografts.